




[19]

| | |
|--|---|
| [11] Patent No.: GC 0000215 | Number of the Decision to Grant the Patent: 5/982 |
| [45] Date of Publishing the Grant of the Patent: 29/03/2006 5/2006 | Date of the Decision to Grant the Patent: 02/07/2005 |
| [21] Application No.: GCC/P/2000/1073 [22] Filing Date: 02/12/2000 [30] Priority: [31] Priority No. [32] Priority date [33] State 9928561.1 02/12/1999 GB 0003500.6 15/02/2000 GB [72] Inventor: Michael Lawrence Sierra [73] Owner: Glaxo Group Limited, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, United Kingdom [74] Agent: Suleiman Ibrahim Al-Ammar | [51] Int.Cl. ⁷ : CO7D 263/34, 277/56, 401/04; A61K [56] Cited Documents: - WO 99 18066 A (SANKYO CO) 15 April 1999 - WO 99 46232 A (ONO PHARMACEUTICAL CO) 16 September 1999 - WO 97 36579 A (GLAXO GROUP LTD; WILLSON TIMOTHY MARK (US)) 09 October 1997 |

[54] SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS HPPAR ALPHA ACTIVATORS

[57] Abstract: A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof



Wherein; X₁ represents O or S; R¹ and R² independently represent H, halogen, -CH₃ and -OCH₃; n represents 1 or 2; X₂ represents NH, NCH₃ or O; One of Y and Z is N, and the other is O or S; R³ represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one or more halogen, NO₂, NH₂, CF₃, OCF₃, OC₁₋₆ straight or branched alkyl, C₁₋₆ straight or branched alkyl, alkenyl or alkynyl with the provision that when R³ is pyridyl, the N is unsubstituted; R⁴ represents CF₃ or CH₃.

No. of claims: 23